Biohaven’s migraine drug NURTEC™ ODT receives FDA approval
Category: #health  By Pankaj Singh  Date: 2020-02-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Biohaven’s migraine drug NURTEC™ ODT receives FDA approval

A clinical-stage biopharmaceutical company, Biohaven Pharmaceutical Holding Company Ltd. recently announced that the FDA has approved NURTEC™ ODT, which has been developed for the acute treatment of migraine in adults. The drug is the first FDA approved product of Biohaven, which is focused upon advancing innovative therapies for neurological diseases.

Consumption of a quick-dissolving NURTEC ODT (rimegepant) tablet can provide fast pain relief and aid patients to function normally within an hour. The drug delivers prolonged efficacy that lasts up to 48 hours for most of the patients. However, rimegepant is not meant for the preventive treatment of migraine. Biohaven is expecting favorable results from its prevention of migraine trial in the coming months.

Vlad Coric, M.D. and CEO of Biohaven Pharmaceutical Holding was reportedly quoted saying that the approval of NURTEC ODT by FDA marks an important milestone for the migraine community and is also a transformative event for the company. Millions of people who are suffering from migraine are not satisfied with their current acute treatment because of the significant tradeoffs; reduced ability to function and troublesome side effects.

NURTEC ODT can be considered an important novel oral acute treatment for migraine that has the potential to instantly reduce and eliminate pain as well as aid patients to get back to their lives normally.

Coric added saying that NURTEC ODT will be the first of many innovative medicines created by the company to become available to treat dreadful neurological diseases, a therapeutic category many other companies have neglected. He further added that Biohaven is dedicated to helping patients with such conditions, who often have limited/no treatment options, to live better and more productive lives.

With quick-dissolve oral tablet formula, NURTEC ODT works by blocking CGRP receptors (a G-protein-coupled receptor of the B subtype), thereby treating the roots of migraine. The drug is not narcotic or opioid, does not have addiction potential and is not scheduled as a controlled substance by the United States Drug Enforcement Administration.  

Source Credit: https://www.prnewswire.com/news-releases/biohavens-nurtec-odt-rimegepant-receives-fda-approval-for-the-acute-treatment-of-migraine-in-adults-301013021.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

TikTok to donate 4 Lakh safety suits to Indian healthcare workers
TikTok to donate 4 Lakh safety suits to Indian healthcare workers
By Pankaj Singh

Amidst lowering availability of medical equipment and safety gear in India during the current COVID-19 crisis, Chinese video-sharing company, TikTok has made a generous gesture by announcing that it will donate ab...

Inzomelid declares positive CAPS treatment results, completes Phase I
Inzomelid declares positive CAPS treatment results, completes Phase I
By Pankaj Singh

Inflammasome biotech company Inflazome has reportedly announced the successful completion of Inzomelid’s Phase I clinical study. In addition, the firm has also declared that it has observed positive results from ...

Flipkart to re-open its online portal to deliver essential products
Flipkart to re-open its online portal to deliver essential products
By Pankaj Singh

Flipkart, a renowned Indian e-commerce company, reportedly announced that it would be re-starting its online portal to deliver essential commodities across India. The company had closed down all its operations on Wedne...